Altrinsic Global Advisors Llc decreased its stake in Jd Com Inc (JD) by 67.68% based on its latest 2018Q1 regulatory filing with the SEC. Altrinsic Global Advisors Llc sold 36,736 shares as the company’s stock declined 24.45% with the market. The institutional investor held 17,540 shares of the consumer services company at the end of 2018Q1, valued at $710,000, down from 54,276 at the end of the previous reported quarter. Altrinsic Global Advisors Llc who had been investing in Jd Com Inc for a number of months, seems to be less bullish one the $58.87B market cap company. The stock decreased 0.53% or $0.22 during the last trading session, reaching $41.25. About 15.55M shares traded or 19.93% up from the average. JD.com, Inc. (NASDAQ:JD) has declined 10.12% since June 14, 2017 and is downtrending. It has underperformed by 22.69% the S&P500. Some Historical JD News: 08/05/2018 – JD.COM SEES 2Q REV. 120B YUAN TO 124B YUAN; 16/04/2018 – ALLIANZ CHINA GENERAL INSURANCE SAYS JD.COM’S UNIT TO INVEST 536.6 MLN YUAN FOR 33.33 PCT STAKE IN THE COMPANY; 17/05/2018 – WALMART – QTRLY ADJ SHR EXCLUDES IMPACT FROM UNREALIZED LOSS OF $0.47 ON EQUITY INVESTMENT IN JD.COM DUE TO CHANGE IN ACCOUNTING PRINCIPLES; 27/04/2018 – iQlYl and JD.com Announce Exclusive Strategic Partnership to Drive Growth of Paid Memberships; 16/04/2018 – JD.com takes $85mn stake in Allianz China unit; 16/03/2018 – JD.com’s finance unit aims to raise $1.9 bln, valuation set to double; 16/03/2018 – https://t.co/l0RHwJq452’s finance arm is fundraising at a $20 billion valuation https://t.co/XcZADWad7E JD.com cnb.cx/2Gzh1vX; 08/05/2018 – JD.COM – ANNUAL ACTIVE CUSTOMER ACCOUNTS UP BY 27.6% TO 301.8 MLN IN 12 MONTHS ENDED MARCH 31, 2018 FROM 236.5 MLN IN 12 MONTHS ENDED MARCH 31, 2017; 08/05/2018 – JD Com 1Q EPS 17c; 08/05/2018 – JD.COM 1Q ADJ EARNINGS PER ADS 71 RMB CENTS, EST. 82 RMB CENTS
Archford Capital Strategies Llc increased its stake in Astrazeneca Plc Sponsored Adr (AZN) by 175.22% based on its latest 2018Q1 regulatory filing with the SEC. Archford Capital Strategies Llc bought 46,976 shares as the company’s stock rose 8.34% while stock markets declined. The institutional investor held 73,786 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $2.56 million, up from 26,810 at the end of the previous reported quarter. Archford Capital Strategies Llc who had been investing in Astrazeneca Plc Sponsored Adr for a number of months, seems to be bullish on the $90.75 billion market cap company. The stock increased 0.06% or $0.02 during the last trading session, reaching $36.18. About 2.48M shares traded. AstraZeneca PLC (NYSE:AZN) has risen 7.86% since June 14, 2017 and is uptrending. It has underperformed by 4.71% the S&P500. Some Historical AZN News: 24/05/2018 – AstraZeneca Heads to 2018 ASCO Annual Meeting with Its Diversified Oncology Portfolio and Next-Generation Pipeline; 18/05/2018 – AstraZeneca PLC 1Q EPS 27c; 16/05/2018 – GENENTECH – IN PHASE lll IMPOWER150 STUDY, SURVIVAL ADVANTAGE FOR TECENTRIQ-AVASTIN COMBO REGIMEN WAS SEEN IN ALL EXPLORATORY PATIENT SUBGROUPS ANALYZED; 12/03/2018 – ADVAXIS: STUDY OF AXALIMOGENE FILOLISBAC W/ IMFINZI ON HOLD; 22/03/2018 – ASTRAZENECA PLC AZN.L – LOKELMA IS CURRENTLY UNDER SEPARATE REGULATORY REVIEW IN US, WITH A DECISION EXPECTED IN FIRST HALF OF 2018; 26/03/2018 – Seattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For Enfortumab Vedotin In Locally Advanced Or Metastatic Urothelial Cancer; 19/03/2018 – ASTRAZENECA – OVERALL, ADVERSE EVENTS OCCURRED IN 41.9% OF PATIENTS WITH DAPAGLIFLOZIN AND 47.8% WITH PLACEBO IN STUDY; 13/03/2018 – ASTRAZENECA IS SAID TO WEIGH $500M SALE OF SEROQUEL DRUG; 24/04/2018 – ASTRAZENECA PLC AZN.L – REPORTS RESULTS FROM ARCTIC TRIAL IN THIRD-LINE NON-SMALL CELL LUNG CANCER; 20/03/2018 – Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
Among 22 analysts covering JD.com (NASDAQ:JD), 16 have Buy rating, 0 Sell and 6 Hold. Therefore 73% are positive. JD.com had 52 analyst reports since August 4, 2015 according to SRatingsIntel. Nomura upgraded it to “Buy” rating and $35 target in Friday, January 22 report. The stock of JD.com, Inc. (NASDAQ:JD) earned “Hold” rating by Bernstein on Wednesday, January 31. JP Morgan upgraded the shares of JD in report on Monday, January 9 to “Overweight” rating. The firm earned “Buy” rating on Thursday, August 11 by Jefferies. The rating was maintained by Jefferies with “Buy” on Tuesday, October 3. The firm has “Underperform” rating by Bernstein given on Wednesday, January 11. The firm has “Buy” rating by Jefferies given on Friday, June 16. The firm has “Buy” rating by Jefferies given on Monday, July 17. Nomura maintained JD.com, Inc. (NASDAQ:JD) on Tuesday, November 14 with “Buy” rating. The company was downgraded on Tuesday, September 20 by M Partners.
Analysts await JD.com, Inc. (NASDAQ:JD) to report earnings on August, 13. They expect $-0.02 earnings per share, down 200.00% or $0.04 from last year’s $0.02 per share. After $0.17 actual earnings per share reported by JD.com, Inc. for the previous quarter, Wall Street now forecasts -111.76% negative EPS growth.
Altrinsic Global Advisors Llc, which manages about $14.11 billion and $2.48 billion US Long portfolio, upped its stake in Kura Oncology Inc by 20,000 shares to 80,000 shares, valued at $1.50 million in 2018Q1, according to the filing. It also increased its holding in Verizon Communications Inc (NYSE:VZ) by 6,852 shares in the quarter, for a total of 498,497 shares, and has risen its stake in Intercept Pharmaceuticals In (NASDAQ:ICPT).
More notable recent JD.com, Inc. (NASDAQ:JD) news were published by: Seekingalpha.com which released: “JD: Why Is It Down So Much?” on June 06, 2018, also Seekingalpha.com with their article: “Buy Alibaba – Cramer’s Lightning Round (6/12/18)” published on June 13, 2018, Nasdaq.com published: “Professor Dingbo Xu Joins JD.com’s Board of Directors” on May 22, 2018. More interesting news about JD.com, Inc. (NASDAQ:JD) were released by: Fool.com and their article: “Here’s How 10 Big IPOs Are Doing Now” published on June 14, 2018 as well as Seekingalpha.com‘s news article titled: “Who Would Buy JD Now?” with publication date: May 17, 2018.
More notable recent AstraZeneca PLC (NYSE:AZN) news were published by: Streetinsider.com which released: “Lilly (LLY) and AstraZeneca (AZN) Halt Phase 3 Trials of Lanabecestat for Alzheimer’s Disease Due to Futility” on June 12, 2018, also Fool.com with their article: “Can This Pharma’s $14 Billion Bet Succeed?” published on June 12, 2018, Seekingalpha.com published: “FDA’s OKs AstraZeneca’s Lokelma for hyperkalemia” on May 21, 2018. More interesting news about AstraZeneca PLC (NYSE:AZN) were released by: Bizjournals.com and their article: “Why Big Pharma is finally discovering the Bay Area” published on May 23, 2018 as well as Seekingalpha.com‘s news article titled: “An Alzheimer’s Statement” with publication date: June 13, 2018.
Archford Capital Strategies Llc, which manages about $349.45 million and $239.94M US Long portfolio, decreased its stake in American Wtr Wks Co Inc New Com (NYSE:AWK) by 46,955 shares to 15,815 shares, valued at $1.45M in 2018Q1, according to the filing.
Among 27 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 17 have Buy rating, 0 Sell and 10 Hold. Therefore 63% are positive. AstraZeneca plc (ADR) had 46 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was initiated by Piperjaffray with “Overweight” on Friday, September 23. On Tuesday, January 19 the stock rating was upgraded by Barclays Capital to “Equal-Weight”. The firm has “Hold” rating given on Monday, October 16 by Cowen & Co. The firm has “Buy” rating by S&P Research given on Friday, July 31. The company was upgraded on Friday, December 29 by JP Morgan. Morningstar maintained the stock with “Hold” rating in Tuesday, June 12 report. The stock of AstraZeneca PLC (NYSE:AZN) has “Buy” rating given on Monday, September 14 by Deutsche Bank. On Tuesday, February 6 the stock rating was maintained by Leerink Swann with “Market Perform”. The firm earned “Hold” rating on Tuesday, March 15 by Jefferies. The firm has “Buy” rating by Swedbank given on Friday, July 31.